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This review is aimed to highlight the importance of stress and glucocorticoids (GCs)
in modulating the inflammatory response of brain microglia and hence its potential
involvement in Parkinson’s disease (PD). The role of inflammation in PD has been
reviewed extensively in the literature and it is supposed to play a key role in the course
of the disease. Historically, GCs have been strongly associated as anti-inflammatory
hormones. However, accumulating evidence from the peripheral and central nervous
system have clearly revealed that, under specific conditions, GCs may promote brain
inflammation including pro-inflammatory activation of microglia. We have summarized
relevant data linking PD, neuroinflamamation and chronic stress. The timing and duration
of stress response may be critical for delineating an immune response in the brain
thus probably explain the dual role of GCs and/or chronic stress in different animal
models of PD.
Keywords: corticosterone, glucocorticoids, microglia, neuroinflammation, neurodegeneration, stress, Parkinson’s
disease
Role of Inflammation in Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder second only to Alzheimer’s disease
(AD) in prevalence. It is characterized by the loss of the dopaminergic neurons in the
substantia nigra (SN) and the accumulation of α-synuclein (α-syn) and other proteins in
intracellular proteinaceous aggregates called Lewy bodies (LB). Familiar forms of PD, usually
appearing under the age of 40 and accounting for no more than 5% of cases, are due to
mutations in a reduced number of genes including SNCA, PINK1, PARKIN and LRRK2
among few others. Idiopathic forms, usually affecting people from 65 years old, have an
obscure etiology; mitochondrial dysfunction, toxins, oxidative stress, infections, decrease
of trophic factors, impairment of the ubiquitine-proteosome system, metabolic alterations,
inflammation and the accumulative effect of a number of susceptibility genes have been
proposed to explain the initiation and development of this form, which accounts for 95% of cases.
Neuroinflammation
Neuroinflammation seems to be an underlying process in many cases of PD. In McGeer
et al. (1988) reported the presence of reactive microglia and inflammatory macrophages as
well as proinflammatory cytokines in SN postmorten samples from PD patients. Considering the
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brain was believed to have immune privilege,these inflammatory
signs were thought to be a response from the microglial system
to neuronal death. The brain is no longer considered to be
immunoprivileged; in fact, infiltration of lymphocytes into
the brain parenchyma of PD patients has been demonstrated
(Brochard et al., 2009); the role of T lymphocytes in PD will be
reviewed in ‘‘Chronic Stress and Parkinson’s Disease inHumans’’
Section).
It is now thought that neuroinflammation could be a
triggering mechanism of neuronal death. Inflammatory animal
models based on the injection of proinflammatory compounds
as LPS, thrombin or tissue plasminogen activator within the
SN have shown that the induction of an inflammatory process
can induce the death of dopaminergic neurons (Castaño
et al., 1998, 2002; Herrera et al., 2000; Kim et al., 2000;
Carreño-Müller et al., 2003; de Pablos et al., 2005, 2006;
Tomás-Camardiel et al., 2005; Hernández-Romero et al.,
2008; Villarán et al., 2009; Argüelles et al., 2010). Evidence
supporting the inflammatory hypothesis of neurodegeneration
also comes from studies showing the expression of a bunch
of inflammatory markers within the brain including specific
proteins, pro-inflammatory cytokines and markers of active
glial cells (for a schematic review of the effects of LPS on
neurons and glial cells found by our group, see Figure 1).
An altered expression of immune signaling-related transcripts
have been described in early stages of PD in a study of
microarray analysis of nucleated blood cells (Soreq et al.,
2008). Epidemiological studies evidence the protective effect of
several nonsteroidal anti-inflammatory drugs, whereas genetic
studies show that polymorphisms in some pro-inflammatory
cytokines may influence the risk of developing PD (Klegeris
et al., 2007). Some studies have shown that classical steroid
anti-inflammatory drugs, such as dexamethasone (Castaño et al.,
2002), as well as drugs used for quite different goals, such as
minocycline (Tomás-Camardiel et al., 2004) and simvastatin
(Hernández-Romero et al., 2008), are able to reduce the
inflammatory process and neuronal death induced by LPS.
Thus, it seems that the pro-inflammatory hypothesis is not
merely possible but likely. The question here is how such an
inflammatory process is initiated within the brain and endlessly
self-sustained.
Not all brain structures exhibit a similar sensitivity to pro-
inflammatory compounds; whereas the SN seems to be very
sensitive, the hippocampus appears to be resistant to LPS
(Espinosa-Oliva et al., 2011). This could be in part related to
differences in the number of microglial cells between brain
structures (Lawson et al., 1990). However, an inflammatory
process induced for LPS can be developed in the hippocampus
of stressed animals (Espinosa-Oliva et al., 2011), suggesting that
the inflammatory responses can be modulated. Unfortunately,
the factors triggering this brain inflammatory response are yet
not known.
Dopaminergic neurons seem to be especially sensitive to a
number of factors that can induce cell damage and eventually
cell death. Dying neurons release substances that are recognized
by glial cells, activating them. Amongst the substances released
by damaged/dying dopaminergic neurons, this review will
focus on three of them: dopamine (DA), neuromelanin (NM)
and α-syn.
Dopamine
DA is the neurotransmitter that defines the dopaminergic
phenotype. It is synthesized from tyrosine in a two-reaction
process catalyzed by the enzymes tyrosine hydroxylase (TH,
the key enzyme in the synthetic pathway of DA) and aromatic
amino acid decarboxylase (AADC), which transform tyrosine
in L-3,4-dihydroxyphenylalanine (L-DOPA) and then L-DOPA
into DA, respectively. The loss of DA is the hallmark of PD
and explains most of the motor alterations of this disease.
Thus, replenishing DA levels is a major therapeutic target
in PD. This is achieved by the combined administration of
L-DOPA, the precursor of DA, and an inhibitor of peripheral
AADC; unfortunately, L-DOPA cannot be freely administered
because many patients develop L-DOPA-induced dyskinesias.
After its release in synapses and signaling on its receptors,
DA can be taken up by glial cells and also by the presynaptic
neurons through the specific DA transporter. Uptaken DA
can be revesiculated in neurons by the vesicular monoamine
transporter 2, but part of it can remain free in the cytoplasm,
where it is metabolized by the monoamine oxidase enzyme to
yield 3,4-dihydroxyphenylacetic acid. Free cytoplasmic DA can
also autooxidize, forming DA quinones and semiquinones able
to react with cysteines residues to form adducts that impair the
function of proteins; for example, DJ-1, a redox sensor protein
involved in recessive forms of familial PD, is covalently modified
by DA and highly reactive DA quinones thus impairing DJ-1
function (Girotto et al., 2012). High cytosolic concentrations of
free DA can lead to oxidative stress as well as to its interaction
with α-syn, both of them initiating the neurodegenerative process
(Mosharov et al., 2006). Strikingly, DA seems to play a role in
the inflammatory response induced by the intranigral injection
of LPS, since experimental depletion of DA caused by the
inhibition of TH by α-methyl-p-tyrosine (α-MPT) prevents
glial activation and loss of dopaminergic neurons (de Pablos
et al., 2005). Bypassing TH inhibition (using the combination
of L-DOPA plus an inhibitor of the peripheral AADC enzyme,
just the composition of several anti-parkinsonian therapies
as SINEMEDr or MADOPARr, for example) reverses the
protective effect induced by α-MPT. Furthermore, depletion
of DA content by α-MPT is able to reduce the infiltration of
peripheral macrophages as well as the increase of microglial
cells induced by the injection of 6-hydroxydopamine (6-OHDA)
within the SN (de Pablos et al., 2014). Thus, DA could have
a relevant role in sustaining inflammation and lymphocyte
recruitment within the brain; in fact, DA could be involved in the
degeneration of dopaminergic neurons induced by inflammatory
processes.
DA, however, may play a beneficial role controlling systemic
inflammation. In a recent article, Yan et al. (2015) show
that DA inhibits the activation of the NLRP3 inflammasome
through D1 receptor (DRD1) signaling. DRD1 activation
stimulates adenylate cyclase activity; the resulting cAMP binds to
NLRP3, promoting its ubiquitination by the E3 ubiquitin ligase
MARCH7. Degradation of the ubiquitinated NLRP3 prevents the
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 August 2015 | Volume 9 | Article 312
Herrera et al. Inflammation and stress in Parkinson’s disease
FIGURE 1 | Average values of some parameters measured in the SN
(as percentage of controls) after the single intranigral injection of 2µg
of LPS. Parameters that increase: OX-42/OX-6, density of activated microglial
cells; amounts of the proinflammatory cytokines TNF-α and IL-1β; the inducible
nitric oxide synthase (iNOS) enzyme; the amount of carbonyl groups (oxidized
proteins); the expression of BDNF (this neurotrophin is associated to cell
survival, but it can have a damaging role under the oxidative conditions induced
by LPS); the phosphorylated (active) forms of the MAP kinases p38, JNK, ERK
and GSK-3β (associated with promotion of apoptosis); the expression of AQP4;
the adhesion molecule ICAM-1; the heat shock proteins (HSP)-27 and 70.
Parameters that decrease: DA/TH/DAT, dopamine content, neurons expressing
tyrosine hydroxylase and dopamine transporter; the phosphorylated forms of
the MAP kinase Akt and the transcription factor CREB (cell surviving signals).
Alterations on the expression of GFAP and the endothelial barrier antigen (EBA),
as area lacking expression (in mm2), are also shown. Loss of expression of
GFAP and EBA is associated to BBB damage.
inflammasome-dependent inflammation. Acting on DRD1, DA
is even able to prevent systemic inflammation induced by LPS,
proving that DA has an important role as a messenger in the
periphery. Consequently, these authors point out to DRD1 as
a potential target for the treatment of inflammatory processes
driven by NLRP3.
Neuromelanin
NM is a dark, complex endogenous polymer derived from DA
that stains dopaminergic neurons and give the name to the
SN; loss of pigmentation is evident in the SN of PD patients
due to the loss of dopaminergic neurons. Free melanin was
already observed in the SN of postmorten samples from PD
patients studied for McGeer et al. (1988). Several studies have
shown that NM is able to induce microglial activation, initiating
neuroinflammation and neurodegeneration of dopaminergic
neurons (Wilms et al., 2003; Zecca et al., 2008; Karlsson and
Lindquist, 2013; Nie et al., 2013). Viceconte et al. (2015) has
shown that synthetic NM is able to activate microglial cells,
both in vitro and in vivo, through a mechanism mediated by
caspase-8 and caspase-3/7. They found in vivo upregulation
of the M1 marker CD16/32 induced by NM, as well as
chemotactic response to NM for the microglial-derived cell
line BV2, accompanied by features of microglial activation
as morphological changes, increase of oxidative stress and
induction of pattern recognition receptors as TLR2, NOD2 and
CD14. Thus, release of NM from damaged/dying dopaminergic
neurons can trigger a self-induced cycle of neuron damage,
release of NM and neuroinflammation with dire consequences
for these neurons.
Alpha-Synuclein
As it was mentioned above, some cases of familiar PD are due
to mutations in a number of genes related with mitochondrial
function, so as neurons lose their capacity to produce the
required amount of energy and thus die, activating and attracting
glial cells. In other cases, polymorphisms in inflammatory
genes seems to be associated with the disease, including pro-
inflammatory cytokines such as TNF-α and IL-1β and their
receptors (Krüger et al., 2000; McGeer et al., 2002; Schulte et al.,
2002; Wahner et al., 2007; Wu et al., 2007; Nie et al., 2013), as
well as TREM2 (Rayaprolu et al., 2013). An increasing number
of GWAS studies have provided possible genetic associations
with the disease, as that found for HLA for example (Hamza
et al., 2010), supporting the role of the immune system in the
development of PD.
A great proportion of these hereditary forms of PD are
related to α-syn, a presynaptic protein involved in vesicle
transport among other functions not fully known (Maroteaux
et al., 1988). α-syn aggregation seems to be an important
event in the development of PD (Marques and Outeiro,
2012; Kalia et al., 2013). Several point mutations in the
SNCA gene are directly related to familial forms of PD
(Polymeropoulos et al., 1997; Krüger et al., 1998; Zarranz
et al., 2004; Lesage et al., 2013; Proukakis et al., 2013). Over-
expression of wild type α-syn due to duplication or even
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triplication of the gene is also related with PD, suggesting that
an excessive amount of the normal protein is also involved
in damaging processes (Singleton et al., 2003; Ross et al.,
2008).
As mentioned above, interactions between α-syn and DA
might play an important role in the death of dopaminergic
neurons: oligomeric forms of α-syn can produce leakage of
DA from presynaptic vesicles into the cytosol (Volles et al.,
2001), and high cytosolic concentrations of DA may in turn
promote the accumulation of α-syn protofibrils (Conway et al.,
2001). Wild-type α-syn can be modified by DA, resulting in
the inhibition of chaperone-mediated autophagy (CMA), which
impairs degradation of α-syn and other substrates of CMA
(Martinez-Vicente et al., 2008). Furthermore, neuron-released
α-syn fibrils that have been phagocytized by microglia can
induce the release of IL-1β through the activation of the NLRP3
inflammasome (Codolo et al., 2013). It is well known that
IL-1β is one of the main and most abundant pro-inflammatory
cytokines affecting inflammatory processes (Dinarello, 2010),
having harmful effects on dopaminergic neurons (Ferrari et al.,
2006; Koprich et al., 2008). The role of IL-1β on inflammation
and dopaminergic neurodegeneration will be discussed later.
All these evidence suggest that interactions between α-syn and
DA might trigger a self-sustained loop leading to neuronal
death.
Braak et al. (2003) postulated the hypothesis that pathology
of PD in the brain could start in structures such as the
olfactory nucleus and the dorsal motor nuclei, progressing from
them to the midbrain and cortex by the spreading of α-syn
seeds. The possible mechanism for cell-to-cell transmission of
pathogenic proteins in neurodegenerative diseases has been
beautifully revised by Guo and Lee (2014). In brief, naked-
protein oligomers seeds can be released from neurons, reaching
other neurons directly through the plasmamembrane or entering
by endocytosis. Seeds can also be released within exosomes
that fuse with the receiving cell membrane. Intracellular
transfer by nanotubes connecting cells is also hypothesized.
It is now clear that α-syn can be found outside cells (for
a review, see Guo and Lee, 2014), and several studies have
shown that α-syn activates microglia into a pro-inflammatory
state (for a very interesting and deep review on microglial
activation by α-syn, see Sanchez-Guajardo et al., 2015). Thus,
α-syn might be an answer to the question stated above:
an inflammatory process can be initiated within the brain
and endlessly self-sustained upon activation of microglia
by extracellular α-syn. However, some questions regarding
neuroinflammation and α-syn are still under debate, as whether
neuroinflammation is causing α-syn misfolding and aggregation,
or the role of neuroinflammation favoring or delaying the
cell-to-cell transfer of α-syn; namely, if α-syn aggregation is
a cause of neuroinflammation or just a consequence of it
(Lema Tomé et al., 2013). In any case, neuroinflammation
and α-syn aggregation form a positive feedback loop that
increases protein aggregation and neuronal damage in PD.
Strikingly, the release of α-syn from neurons, with its
consequent arrival to other neurons, can be initiated outside the
brain.
Given the significant role of inflammation in PD
pathogenesis, and considering the influence of stress/
glucocorticoids (GCs) in microglia polarization, we will next
discuss most relevant aspects of stress and microglia activation
as well as their likely influence on PD.
Stress
Organisms, both simple and complex, have developed
mechanisms to deal with the different challenges that occur
during their lifetime. Stress is a condition of human experience
and also an important factor in the onset of several diseases,
including cardiovascular, metabolic and neuropsychiatric
diseases (Renard et al., 2005; Musazzi et al., 2010). Stress is a
term commonly used to describe internal states or feelings and,
as a consequence, the interpretation of its meaning is often
subjective, making it difficult to assess how it impacts upon our
body (Miller and O’callaghan, 2005).
The term stress would be difficult to understand without the
concepts developed by the physiologists Claude Bernard and
Walter Cannon. Whilst the former described the concept of
internal environment (Millieu Interieur), the latter introduced
the term homeostasis to define the combination of physiological
mechanisms that together maintain the stability of the internal
environment. Homeostasis is achieved via different systems
which cooperatively counteract internal or external factors
that tend to modify it. Based on these concepts, Selye (1946)
coined the term stress as a ‘‘general adaptation syndrome’’.
Of note, the cortico-adrenal activation is the most important
physiological aspect of stress. Selye would futher introduce
the term stressor as the stimulus that causes the syndrome,
narrowing the definition of stress as the body’s response
to such stimulus. However, although numerous scientific
articles on stress have been published in recent decades, the
definition of stress remains complex, controversial and somehow
ambiguous.
Under stressful situations, humans mobilize physiological
resources to respond to these situations in the so-called stress
response (Van de Kar and Blair, 1999). Different variables
influence the individual response to these threats. Among these
stand stressors (depending on the type, severity or repetition
of events), individual factors (such as vulnerability, emotional
stability and coping styles) and environmental variables. The
interaction of these variables can lead to various stress responses
from the physiological point of view, in which brain (information
processing), autonomic (innate system) and neuroendocrine
(adaptative system) activation are involved. Although they are
individual systems, in practice their functions overlap at some
point. All these responses constantly feedback the body to
increase, maintain or decrease the stress response.
Systems Activated by Stress
When an organism is stressed, two different systems are
activated: the Sympathetic-adrenal-medullary system (SMA) and
the Hypothalamic-pituitary-adrenal system (HPA). Initially, a
threatening stimulus excites a receptor leading this information
to the brain in the form of nerve impulses. The sensory
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information is then projected on the associative thalamic nuclei
from where it continues its journey to the cerebral cortex (Van
de Kar and Blair, 1999), which is responsible for modulating
the sensory processing and identify if there is a threatening
stimulus or not. The activation is promoted by the action of the
reticular formation that starts the general excitation. Amongst
other things, the anterior cingulate cortex changes the priorities
of attention and concentration (Botvinick et al., 2001), whilst the
frontal cortex generates the plan of priorities for attention skills
and working memory (Rushworth et al., 2004).
If not valued as stressful, the body’s response would involve
the implementation of normal, specific homeostatic mechanisms
that are appropriate for the particular situation. If it is
considered stressful, the emergency mechanisms that constitute
the stress response (activation of SMA and HPA axes, autonomic
arousal and neuroendocrine activation) would become activated
(Finsterwald and Alberini, 2014). This may occur because the
stimulus is qualitatively stressful for all individuals of a particular
species or because it exceeds a certain threshold of intensity.
When the nerve-center activation appears to have peaked,
autonomic activation occurs, activating the SMA axis. This, in
turn, prepares the body to cope with the external threat and
to facilitate state of fight-or-flight response, so that the internal
environment is maintained uniform (homeostasis; Finsterwald
and Alberini, 2014).
Once the reticular formation has begun the process
of general activation, the hypothalamus is excited. The
hypothalamus is responsible for controlling the functions of
the autonomic nervous system and the endocrine system,
organizing survival behaviors such as fighting, feeding, fleeing
and reproduction (Maggi et al., 2015). After the arrival of
the information to the hypothalamus, the primary and quick
response will cause the release of catecholamines (noradrenaline
and adrenaline) from the hypothalamus and the sympathetic
pathway. These catecholamines are responsible for putting
the body on alert in preparation for ‘‘fight–or-flight’’. Some
of the observable physiological effects include tachycardia,
increased blood pressure, sweating and dilated pupils (Ursin
and Olff, 1993). Finally, the neuroendocrine response is
activated, initiated by the HPA axis when neurons in the
paraventricular nucleus (PVN) of the hypothalamus secrete a
peptide called corticotropin releasing factor (CRH). This and
other related hormones enter the private circulatory system
connecting the hypothalamus with the anterior pituitary. Within
seconds, CRH activates the pituitary by inducing the release of
adrenocorticotropic hormone (ACTH; Leng and Russell, 1998).
Once released, ACTH enters into the blood flow and stimulates
the adrenal cortex to release GCs: cortisol, hydrocortisone and
corticosterone. Mineralocorticoids, such as deoxycorticosterone
and aldosterone, alongside sex steroids, such as progesterone,
are also released. The release of GCs in stressful situations aims
to raise the level of glucose in the blood, helps to convert fats
into energy, increases blood flow, and stimulates behavioral
responses; at the same time it inhibits unnecessary vegetative
activities such as digestion, growth, reproduction and immune
system (Stratakis and Chrousos, 1995), to prepare the body to
deal with the emergency.
Corticoids
Glucocorticoid receptors (GRs) are ligand dependent
transcription factors that regulate the expression of several
genes. The appropriate modulation of its expression is critical
for maintenance of cellular homeostasis. Genomic actions of
steroids on CNS are mediated by two types of receptors (de
Kloet et al., 1987, 1993): the glucocorticoid receptor type II
(GR) and the mineralocorticoid receptor type I (MR). Both
differ from each other in their specificity and affinity for
ligands, their location and their function. Inactivated GRs have
a predominantly cytoplasmic localization. Free receptor forms a
complex with a system of chaperone proteins (heat shock protein
or hsp90, hsp70 and hsp40) or with FKBP52 (immunophilins;
Rajapandi et al., 2000; Galigniana et al., 2001; Pratt et al., 2001).
These proteins confer to the receptor high affinity for the
hormone and dissociate from the receptor upon binding the
hormone. However, these proteins also seem to be involved in
the movement of GRs from the cytoplasm to the nucleus along
microtubules (Galigniana et al., 2001; Pratt et al., 2001). When
the hormone binds to the receptor, the complex undergoes a
conformational change that mediates its activation and facilitates
the binding of specific DNA sequences to regulatory or promoter
regions of genes. GCs therefore control gene expression by
activating or inhibiting specific genes.
MR primarily binds to GCs such as corticosterone and
mineralocorticoids such as aldosterone, presenting high
affinity for both, whereas GRs have relatively low affinity for
corticosterone and higher affinity for cortisol and various
synthetic GCs such as dexamethasone. MRs are present in target
organs for mineralocorticoids such as kidney, intestine and
salivary glands, where they regulate the osmotic balance and
salt intake. At the central level, MRs are particularly expressed
in the hippocampus, septum, amygdala, olfactory bulb and in
regions of the cerebral cortex (de Kloet et al., 1993). Within
the hippocampal formation, they abound in the CA1 and CA3
areas as well as in the dentate gyrus, and they have also been
found in lesser amounts in the nucleus of the solitary tract. On
the other hand, GRs present a more widespread distribution
and are therefore present in all tissue types. However, within
the CNS, they are more abundant in the limbic system (septum
and hippocampus), in PVN and in brainstem monoaminergic
areas.
The distinct affinity of both receptors for corticosterone
determines a different degree of occupation depending on
circulating levels of GCs. Thus, when the concentration of GCs
is high, as occurs in rats during the night or after stressful
situations, GRs are the receptors involved. In contrast, MRs are
involved during the light phase, when they play a modulatory
role in the basal levels of the HPA axis (de Kloet et al., 1987).
At the peripheral level, almost all tissues possess GRs and,
in a lesser extent, MRs (Munck et al., 1984). The varying
distribution of these receptors in tissues allows GCs to act
in different metabolic processes that are essential for body
homeostasis. Finally, this general vegetative excitation returns
to the brain, initiating a feedback on internal receptors in
the body. This feedback may result in a further increase in
the overall excitation (sympathetic stimulation) and, conversely,
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a relaxation (parasympathetic stimulation) by decreasing the
excitation.
The effects of GCs on the stress response are important
and necessary. Physiological changes associated with stress
include mobilization of energy to maintain brain and muscle
function, (which sharpens and focuses the attention of the
perceived threat), increased cerebral perfusion rates and local
cerebral glucose utilization, enhanced cardiovascular output and
respiration, redistribution of the blood flow, and modulation
of immune system (Carrasco and Van de Kar, 2003; Filipovi´c
and Pajovi´c, 2009). However, its long-term activation can have
harmful effects on health, such as increased blood pressure,
muscle tissue damage, atherosclerosis, diabetes, inhibition of
immunological responses (Sorrells and Sapolsky, 2007; Tank and
Lee Wong, 2015), and even damage in brain structures such as
the hippocampus (Sapolsky, 1986; McEwen, 1999).
Models of Stress
Depending on the time of exposure, different stress models have
been developed (Jaggi et al., 2011). Exposure to a stressor can last
from seconds to days or weeks, and the effects of stress on the
endocrine system depend on the duration of the exposure and
its impact. If the stressful stimulation is repeated and prolonged
in time, it is considered chronic stress and has been associated
with important psychological and physiological conditions in
humans.
Two types of chronic stress can be distinguished: continuous
chronic stress and intermittent chronic stress. In chronic
continuous stress, the animal may be successively subjected to
stress for days or weeks, whereas in intermittent chronic stress
animals are exposed for a period of weeks to a stressful situation,
with daily exposure time ranging from minutes to hours. As
an example of a model of continuous stress, we could mention
social stress in rodents. This is particularly noticeable when the
aggressive behavior of the male is enhanced by the presence of
females (Blanchard et al., 1993).
The stress model most used experimentally is the intermittent
chronic stress model, in which animals are exposed to a stressful
situation on daily basis. In the literature, the most commonly
used models are exposure to cold, restriction of movement (in
a tube), forced swimming and electric foot shock among others
(Katz et al., 1981; Armario et al., 1988; Riccio et al., 1991).
The chronic variable stress is another model of chronic stress
that shares characteristics with the two types of chronic models
listed above; the animals are daily exposed to different random
stressors, making it difficult to predict the arrival of a particular
stimulus and avoiding the consequent adaptation (Katz et al.,
1981; Armario et al., 1985, 1988).
Dual Roles of Glucocorticoids in Microglia
Activation and Polarization
From a historical perspective, GCs are strongly associated with
anti-inflammatory hormones, as exemplified by the 1950 Nobel
Prize in Physiology or Medicine, awarded jointly to Edward
Calvin Kendall, Tadeus Reichstein and Philip Showalter Hench
‘‘for their discoveries relating to the hormones of the adrenal
cortex, their structure and biological effects’’. In keeping with this
view, the action of GCs in the brain could be solely seen as
inhibitors of pro-inflammatory microglia under conditions of
brain inflammation. However, accumulating evidence from the
peripheral and the central nervous system have revealed that,
under specific conditions, GCs may promote brain inflammation
including the pro-inflammatory activation of microglia. It
is, however, important to highlight that GC actions do not
necessarily have to fully mimic stress actions. From studies in
the peripheral system, it has been established that the timing and
duration of the stress response may be critical for delineating
an immune response (Sorrells et al., 2009). If stress takes place
before immune activation, it may sensitize (prime) immune
cells for a greater response. In this section, we will briefly
summarize literature demonstrating anti- and pro-inflammatory
actions of GCs on brain. Special attention will be paid to
the pro-inflammatory actions of either GCs or stress in the
CNS, considering their relevance in the course of different
neurodegenerative diseases.
Pro- and Anti-Inflammatory Actions of GCs
As already mentioned, the timing of GC administration
may be critical in finally determining a pro- or an anti-
inflammatory action. Supporting this idea, it has been shown
that in vitro treatment of microglia with GCs decreases the
ability of these cells to produce interferon-gamma (IFN-γ) and
tumor necrosis factor-alpha (TNF-α) in response to stimulation
with lipopolysaccharide (LPS; Tanaka et al., 1997). In similar
conditions, dexamethasone suppresses LPS-induced nuclear
factor kappa B (NF-κB) activation in the brain (Glezer et al.,
2003). Interestingly, NF-κB has been involved in the resolution
of inflammation (Lawrence and Fong, 2010; Taoufik et al., 2011).
Similarly, GCs suppress microglial toxic radical production
(Colton and Chernyshev, 1996; Drew and Chavis, 2000) and
cell proliferation (Woods et al., 1999). Exogenous corticosterone
abolishes cytokine gene expression inmicroglia (Blais et al., 2002;
Nadeau and Rivest, 2003). Together, these studies point out that
GCs are able to directly inhibit microglia function and suggest
a possible role for GCs in the regulation of microglia function
in vitro. Stress-related GCs, when applied after an inflammatory
challenge, are also anti-inflammatory. Thus, post-LPS acute
stress decreases the production of pro-inflammatory cytokines
(Goujon et al., 1995). Systemic LPS has been associated to GCs
increase. Interestingly, adrenalectomy potentiates the increase of
brain cytokines produced by systemic LPS. Consequently, GCs
released upon LPS treatment inhibit the inflammatory response
triggered by LPS.
Even though GCs may exert immunosuppressive actions
on microglia, it is becoming evident that they may also play
opposite roles, this effect being particularly evident if GCs
or stress are applied before a pro-inflammatory challenge.
The administration of GCs prior to a systemic LPS challenge
exacerbates brain inflammation in terms of up-regulation of
mRNA expression of interleukin-1β (IL-1β) and TNF-α in
the hippocampus (Frank et al., 2010). However, under the
same experimental conditions, GCs diminishes the expression
of pro-inflammatory cytokines when given 1 h after LPS
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challenge (Frank et al., 2010). In this study, GCs act as pro-
inflammatory agents at 2 and 24 h before LPS challenge,
thus suggesting that the previous exposure to GCs could
prime microglia (Frank et al., 2010). To demonstrate that
microglia is the target of GC action, the authors isolated
microglia from GC-pretreated rats and further challenged it
ex vivo with LPS. Under these conditions, GCs treatment
further upregulated MHCII and toll-like receptor-4 (TLR-
4), and produced more IL-1β and TNF-α (Frank et al.,
2010), supporting the hypothesis that GCs sensitizes brain
microglia to subsequent pro-inflammatory stimuli. The pro-
inflammatory actions of GCs may be neurotoxic under
conditions associated to neural damage and inflammation.
The effect of GCs under conditions of excitotoxicity induced
by intrahippocampal kainic acid injections are associated to
pyramidal CA3 degeneration and glial response (Dinkel et al.,
2003). In this study, GCs increased the number of hippocampal
immune cells including microglia, up-regulated mRNA and
protein expression of IL-1β and TNF-α, and increased the
kainate-induced lesions in the CA3 region (Frank et al.,
2010). Further evidence that GCs exacerbate the microglial
pro-inflammatory response under conditions of excitotoxicity
derived from hippocampal cultures, where GCs exacerbates KA-
induced expression of pro-inflammatory cytokines (Macpherson
et al., 2005). Different stress paradigms, when applied before an
inflammatory challenge, have also been shown to sensitize pro-
inflammatory microglia. Thus, stress exposure to inescapable
tail shock (Johnson et al., 2002, 2003, 2004) potentiated the
expression of pro-inflammatory mediators (i.e., IL-1β, TNF-α
and inducible nitric oxide synthase, iNOS) in hippocampus,
hypothalamus and frontal cortex, as well as the sickness
response (i.e., fever) produced by a peripheral injection of
LPS given 24 h after the stressor regimen. Similar results
were found after 14 daily sessions of unpredictable chronic
stress (Munhoz et al., 2006) in terms of expression of pro-
inflammatory mediators (TNF-α, IL-1β, iNOS). Subacute stress
also induces GR-dependent microglia proliferation (Nair and
Bonneau, 2006). In this study, the authors used amurine restraint
stress model known to elevate GC levels. Stress maintained for
6 days increased microglia proliferation in vivo. This stress-
induced proliferation of microglia is mediated by GCs since
RU486 (or mifepristone), a potent inhibitor of GR activation,
prevented this effect (Nair and Bonneau, 2006). Besides,
N-methyl-d-aspartate (NMDA) receptor blockage prevented
the proliferating stimulus induced by stress. Further work is
needed to shed light into the role of NMDA receptors in
microglia proliferation since NMDA receptor expression is
mostly located on neurons. A paradigm of inescapable shock
24 h before microglia isolation from hippocampal tissue, and
further plating and treatment with LPS, was used to test if
microglia was the neuroimmune substrate responsible for the
stress-induced pro-inflammatory response (Frank et al., 2007).
This experimental design showed that stress primes microglia
to a subsequent inflammatory challenge. Besides, it was found
that stress downregulated CD200, a neuronal glycoprotein that
maintains microglia in a quiescent state of activation (Hoek et al.,
2000).
We and others have demonstrated that chronic stress
potentiate the microglial pro-inflammatory response (de Pablos
et al., 2006, 2014; Tynan et al., 2010; Espinosa-Oliva et al., 2011;
Wohleb et al., 2011; Hinwood et al., 2012). Psychological chronic
stress-induced inflammatory changes in microglia/macrophages
were blocked by propranolol, an indication of an active
role of β-adrenergic receptors in stress-induced microglial
pro-inflammatory response (Wohleb et al., 2011). GRs but
not MRs seem to have a central role in stress-induced
sensitization of microglia. Blockage of GRs prevents stressor-
induced enhancement of cytokine release (Munhoz et al., 2006).
We and others have demonstrated that blockage of GRs prevents
stress-induced microglial activation (Nair and Bonneau, 2006;
de Pablos et al., 2006; Espinosa-Oliva et al., 2011). Similar
results have been found using inhibitors of GCs synthesis (Nair
and Bonneau, 2006). These studies suggest that GRs are key
mediators in modulating the activation state of microglia.
The role of IL-1β in the stress-induced sensitization of
proinflammatory immune response and GC responses to a
subsequent immune challenge has been analyzed (Johnson
et al., 2004). Intracisternal administration of IL-1 receptor
antagonist 1 h before tail shock completely prevented the
stress-induced enhancement in central and pituitary IL-1β
and plasma IL-6 release following LPS challenge (Johnson
et al., 2004). Central human recombinant IL-1β administration
significantly enhanced elevated central IL-1β levels and plasma
corticosterone following LPS challenge. This study demonstrates
a central role of IL-1β in mediating microglia brain priming
to subsequent immune challenge. More efforts have been
made to uncover how GCs sensitizes brain microglia to
further pro-inflammatory stimuli, thus becoming neurotoxic.
Within this context, and considering the central role of IL-1β
in modulating GC-derived immune responses, the NLRP3
inflammasome (nucleotide-binding domain, leucine-rich repeat,
pyrin domain containing proteins) appears as an attractive
target where GCs may exert its pro-inflammatory action
(Figure 2). NLRP3 senses various stimuli ranging from ATP,
nigericin, uric acid crystals, Escherichia coli and Citrobacter
rodentium (Gurung and Kanneganti, 2015). Activation of the
NLRP3 inflammasome is tightly regulated and requires two
independent signals: a priming step is first needed to drive
transcription of inflammasome machinery. This first signal is
usually facilitated through activation of TLRs or nucleotide-
binding oligomerization-domain protein 2 (NOD2) to initiate
the NF-κB signaling pathway. It should be first highlighted
that GCs increase the activity of the transcription factor NF-κB
(Hermoso et al., 2004; Smyth et al., 2004; Munhoz et al., 2006).
Blockage of TLR2 and TLR4 prevents stress-induced priming
of the microglial pro-inflammatory response, thus supporting
the notion that pro-inflammatory actions of GCs relies, at
least in part, on TLRs signaling (Weber et al., 2013). Once
the machinery of NLRP3 inflammasome is synthesized due
to the priming response, subsequent activation, referred to as
‘‘signal 2’’, results in its oligomerization and inflammasome
assembly, eventually leading to caspase-1-dependent cleavage
and secretion of pro-IL-1β and pro-IL-18 (Figure 2).
GC-induction of NLRP3 could serve as a mechanism for
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FIGURE 2 | The realm of vicious cycles. (A) Microglia priming by stress prior
to an inflammatory challenge. (1) Stress increases glucocorticoids (GCs) levels,
which enter the microglial cell. Once inside, GCs can bind mineralocorticoid and
Glucocorticoid receptors (GRs) or both (here referred to as GR). GR are
normally bound to HSPs. Upon binding, HSPs are released from GR to further
translocate to the nucleus and induce transcriptional machinery (2) that lead to
active secretion of HMGB1 (3), an alarmin well-known for being an endogenous
true-ligand of Toll-like receptors (TLR), including TLR2 TLR4. TLR activation is
known to activate NF-κB (4), thus inducing transcription of the NLRP3
inflammasome machinery (NLRP3, ASC and caspase 1) along with expression
of pro Il-1α and pro IL-18 proteins (caspase-1 substrates). Under these
conditions, microglial cells become primed for a subsequent inflammatory
challenge. (B) Inflammatory challenge in Parkinson’s disease (PD) after stress.
(Continued)
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FIGURE 2 | Continued
Several factors (genetic and/or non genetic) may drive nigral DAergic neurons
to an altered state in which ROS production (for example) are increased (5).
Degenerating cells release different factors, including ATP (6), a well known
inducer of NLRP3 assembly. ROS may induce an excessive production of the
dark polymer neuromelanin (NM) (7), as well as impairs degradation of
misfolded α-synuclein (α-syn) by the ubiquitin proteasome system (UPS) and
potentiate the formation of α-syn oligomers (α-syn-mers) and Lewy bodies
(LB), the most distinctive histopathological feature of PD (8). NM, α-syn
oligomers and LB (this after neuronal death) are released from the dying
DAergic neurons and recognized for different PRRs including TLR2, TLR4 and
RAGE (9). Again, this leads to NF-κB activation and translocation to the
nucleus (10), with the consequent transcription of pro-inflammatory genes
(11); pro-inflammatory cytokines as TNF-α and IL-6 may induce neuronal
death (11). ATP released from the damaged DAergic neurons activate the
purinergic receptor (P2R) on microglial cells, leading to the assembly of the
NLRP3 inflammasome and caspase-1 activation (12). Activated caspase 1
cleaves pro-Il-1α and pro-IL18 to IL-1β and IL-18, which are then released
(13). IL-1β is known to bind IL-1R on DAergic neurons, which may contribute
to cell death (13). Activation of microglia is accompanied by increased activity
of different ROS- and RNS-producing enzymes such as iNOS, NADPH
oxidase and myeloperoxidase (not shown) (14). NADPH oxidase catalyzes the
production of superoxide anion (•O2) from oxygen in response to different
pro-inflammatory stimuli. •O2 reacts with NO (mainly derived from
upregulation of iNOS) to produce peroxynitrite (ONOO-), the most reactive free
radical, thus inducing nitrosative stress. Peroxynitrite can both initiate and
sustain a toxic loop eventually leading to neuronal damage (15), establishing a
self-perpetuating process of neuroinflammation and neurodegeneration.
stress- and GC-induced priming of neuroinflammatory
processes (Figure 2). GCs induce NLRP3 mRNAs and
proteins in primary macrophages (Busillo et al., 2011).
More interesting, these authors found that dexamethasone
enhanced the ATP-induced release of IL-1β, an effect that
was prevented by RU486, thus suggesting that GCs may
sensitize macrophages-derived proinflammatory response by
regulating NLRP3 expression and function (Busillo et al.,
2011). This was confirmed by using a caspase-1 inhibitor,
which completely inhibited the ATP-dependent and GC-
enhanced release of IL-1β (Busillo et al., 2011). Subsequent
studies suggested a similar effect of GCs on microglial cells
(Frank et al., 2014). In this study, microglia was isolated
from adrenalectomized rats and treated with different doses
of GCs to be subsequently challenged with systemic LPS. A
dose-response effect was found in terms of Iba-1, MHCII,
NF-κBIα and NLRP3, in a concentration dependent manner.
Activity of the NLRP3 inflammasome was not measured in
this study. It would be interesting to test the effect of GC
treatment on ATP or nigericin-induced NLRP3 assembly,
caspase-1 activation and IL-1β release. Considering that ATP
is released by injured or dying cells, these findings may explain
why GCs enhances the immune response. Injured and dying
cells release danger-associated molecular patterns (DAMPs).
DAMPs and pathogen-associated molecular patterns (PAMPs)
are detected by TLRs, thus activating the immune system
(Figure 2).
Stress-induced release of DAMPs represents an attractive
molecular link between stress and priming of brain microglia.
Supporting this view, it has been demonstrated that inescapable
tail shock induced high mobility group box-1 (HMGB-1), which
is considered an archetypical alarmin (Frank et al., 2015) in
the hippocampus, along with NLRP3 up-regulation (Weber
et al., 2015). Intracisternal administration of BoxA, an HMGB-1
antagonist prior to stress, prevented the LPS-induced up-
regulation of NLRP3 and proinflammatory cytokines in isolated
cultured microglia (Weber et al., 2015). Interestingly, microglia
isolated from animals subjected to inescapable tail stress was
found to actively secrete HMGB-1, thus bringing a rationale
of how acute/chronic stress or GCs may lead to release of
one or different DAMPs, thus increasing the inflammatory
response to a subsequent pro-inflammatory stimulus. Figure 2
highlights more potential mechanistic events linking chronic
stress and PD.
Effect of Chronic Stress in Animal Models
of Parkinson’s Disease
Animal models of PD based on neurotoxins and the
manipulation of genes implicated in this disease have been
important in elucidating aspects as the molecular basis of
dopaminergic neurons death or the importance of misfolded
proteins in neurodegeneration, respectively (Dauer and
Przedborski, 2003). Although research has deepened into
the pathology and symptoms of PD, the factors involved in the
onset and course of this disease remain to be characterized.
Taken into account the pro-inflammatory effects of GCs on
the CNS and the important role that inflammation plays in the
development of PD, stress have been considered to influence not
only the diversity in symptoms and course of PD within different
patients, but also their individual responses to medication after
the onset of the disease (Foley et al., 2004).
With regards to the effects of stress in different animal models
of PD, recent studies have demonstrated that stress and high
corticosterone levels can exacerbate nigral neuronal loss and
motor symptoms in these animals (Smith et al., 2008; Kelly et al.,
2012; de Pablos et al., 2014). This suggests that the impediment
of functional and structural compensation generated by stress
may be enhancing neurodegenerative processes and thus may
represent a key factor in the pathogenesis of PD.
One of the first studies about the relationship between
PD and stress showed that chronic stress and elevated
corticosterone levels increased neurodegenerative events
and motor deficits in a rat model of PD (Smith et al., 2008).
It is generally acknowledged that intracranial injection of 4
mg/mL of 6-OHDA induces DA depletion (Kostrzewa and
Jacobowitz, 1974; de Pablos et al., 2014). They evaluated the
effects of both chronic restraint stress and oral treatment
with corticosterone, a hormone released under stress
conditions, on motor impairments and neurodegenerative
processes in the unilateral rat model of PD. The authors
showed that chronic psychological stress, such as that
produced by daily restraint, and elevated corticosterone
levels can separately lead to impaired skilled limb use in both
naïve and 6-OHDA DA-depleted rats. Furthermore, in the
6-OHDA injected group, stress and corticosterone treatments
also disturbed limb coordination and altered exploratory
behavior, which was accompanied by an acceleration of the
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neurodegenerative processes and neuronal loss in the SN. All
these findings point out that stress can increase functional
deficits and thus accelerate the loss of DA-producing neurons
(Smith et al., 2008).
Methamphetamine (METH) is known to cause damage to
dopaminergic nerve terminals in the striatum, producing loss
of TH and DA, and an activation of microglia and astroglia
(Seiden et al., 1976; Hotchkiss et al., 1979; Bowyer et al., 1994;
Miller and O’callaghan, 1994; O’callaghan and Miller, 1994;
Ladenheim et al., 2000; Thomas et al., 2004; Fleckenstein
et al., 2007; Krasnova and Cadet, 2009). To suppress this
METH-related neuroinflammation, mice were pre-treated
with corticosterone, both acutely (30 min before METH) and
chronically (1 week before METH; Kelly et al., 2012). Not only
both treatments failed to prevent neuroinflammation responses
to METH, but the striatal neuroinflammatory response to
METH was enhanced when mice were chronically pre-treated.
This effect was further accompanied by enhanced astrogliosis
and dopaminergic neurotoxicity. Furthermore, chronic pre-
treatment also sensitized frontal cortex and hippocampus
to induce a neuroinflammatory response to METH. These
levels of chronic corticosterone are associated with high
physiological stress, suggesting that chronic corticosterone
therapy or sustained physiological stress may sensitize
neuroinflammation and neurotoxicity responses produced
by pro-inflammatory drugs as seen on METH (Kelly et al.,
2012).
In another study showing the negative effects of stress/GCs
(de Pablos et al., 2014), the authors observed that chronic stress
increased both microglial activation and the expression of pro-
inflammatory markers in an animal model of PD based on the
intranigral injection of LPS. Importantly, they reported a higher
inflammatory response in stressed animals which was associated
with an increased death rate in dopaminergic neurons of the SN.
To test whether this effect was related to GCs, they pretreated
the animals with the GR inhibitor RU486. When the animals
received this treatment, both microglial overactivation and the
subsequent neuronal death in response to LPS were prevented,
once again suggesting a potential negative role of stress/GCs in
PD (de Pablos et al., 2014).
Anti-Inflammatory Effects of GCs
However, besides their negative effects, GCs are the most
powerful endogenous immunosuppressors via inhibiting
the transcription of genes involved in the innate immune
response, such as the pro-inflammatory transcription factor
NF-κB (McKay and Cidlowski, 1999). Within this context,
animals treated with RU486 showed a rapid and severe
neurodegeneration after the intracerebral infusion of LPS
(Nadeau and Rivest, 2003). They attributed this effect to
impaired levels of cytokines in the cerebral environment, in
particular TNF-α, as the inhibition of its biological activity was
able to abolish the neurotoxic effect of LPS injection. According
to these data, GCs could play a role as modulators of the innate
immune system in the CNS; therefore, an imbalance on their
immunosuppressive activities may lead to cerebral damage
(Nadeau and Rivest, 2003).
As mentioned before, GCs exert their actions mostly through
ubiquitously expressed type II GRs. Since several reports
have hypothesized a link between GC-GR responses and PD
pathogenesis, several studies have attempted to elucidate the role
of these receptors in regulating dopaminergic neurodegeneration
(Morale et al., 2004; Ros-Bernal et al., 2011). Ros-Bernal et al.
(2011) performed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) injections in mice in which GRs had been selectively
knocked-out in either macrophages/microglia or dopaminergic
neurons. MPTP treatment unleashed an increase in CNS GRs
that was followed by a rapid increment in the number of
microglia colocalizing these receptors. Mice lacking GRs in
microglia but not in dopaminergic neurons experienced a
higher loss of dopaminergic neurons after MPTP intoxication
that could not be prevented by corticosterone. The increased
death of dopaminergic neurons observed in the former was
also correlated with reductions in DA uptake and DA levels
in the striatum. Moreover, the absence of microglial GRs
increased microglial reactivity and continuous activation. The
regulatory role of GRs was confirmed by a higher expression
of pro-inflammatory genes, such as TNF-α, alongside a
decrease in anti-inflammatory genes, as IL1-R2. Together,
these findings point out the potential role for the GC-GR
system in the development of PD, and how GR dysfunction
in PD may result in a subsequent chronic inflammatory
reaction generating a positive feedback (Ros-Bernal et al.,
2011).
Morale et al. (2004) injected MPTP in transgenic mice
that constitutively expressed GR antisense RNA from
early embryonic life. This produced a deficiency in GRs.
They found this deficiency exacerbated the MPTP-induced
toxicity to dopaminergic neurons, so that an increased
loss of tyrosine hydroxylase positive nigral neurons and
a decrease of DA levels in the striatum were observed. In
these mice, microglia produced higher nitrite levels than in
wild-type mice; these increases occurred before the loss of
dopaminergic function. This shows the importance of GRs
in the anti-inflammatory and immunosuppressive effects
of GCs, and establishes a relation between impairment
function of GRs and vulnerability to MPTP (Morale et al.,
2004).
A question arising from these studies is how acute and chronic
stress can trigger opposite effects in terms of brain inflammation
and associated neurodegeneration. The paradoxical actions of
GCs on microglial activation may be associated with differences
in pharmacological approaches, experimental models or steroid
hormone concentrations (Glezer et al., 2003; Macpherson et al.,
2005). However, as mentioned earlier in this review, the timing
and duration of stress responsemay be critical formodulating the
immune response (Sorrells et al., 2009). Although evidence for a
causal relationship between stress and PD has not been defined,
stress could be playing an important role in its pathogenesis.
GRs density differs throughout distinct brain structures and,
interestingly, it is increased in regions involved in motor control,
such as the motor cortex, basal ganglia and cerebellum (Ahima
and Harlan, 1990; Ahima et al., 1992). This might in turn
enhance their susceptibility to the effects of stress in both
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humans (Maki and Mcilroy, 1996) and rats (Metz et al., 2001,
2005).
Therefore, stress might represent a critical variable to
be consider in the progression of neurodegenerative events
underlying PD, where it can contribute to early onset of the
motor symptoms in the presymptomatic stage of the disease as
well as worsen the symptoms of PD once the disease has been
diagnosed (Smith et al., 2008).
Chronic Stress and Parkinson’s Disease in
Humans
Within the medical community, it is generally accepted that
chronic stress can be a contributing factor in the development
of mental illness, metabolic diseases and immune system
suppression, amongst many other physiological dysfunctions.
For instance, it has been recently discovered a genetic
relationship between anxiety and hypertension through
microRNA regulation of the cholinergic pathway (Hanin
et al., 2014). Higher risk of developing a neurological disease
after prolonged emotional stress has already been established in
AD (Rothman and Mattson, 2010). Although this relationship
has not been established yet in PD, some studies prove that
there is a higher prevalence of PD in people suffering stress. For
instance, depression, as well as other chronic stress situations,
increase the prevalence of PD (Schuurman et al., 2002) and
seems to be related to severe symptoms like dyskinesias,
disturbed sleep, and bradyphrenia (Pålhagen et al., 2008). The
relationship between these two pathologies is not well-defined
yet. Some studies estimate a 50% prevalence of depression in
PD patients compared to 11% in non-PD patients (Hemmerle
et al., 2012). Depression has also been proposed as a symptom
for some subtypes of PD (Brown et al., 2011). However, this
poorly understood relationship is due to an overlap of symptoms
between both diseases. Defining depression as a previous stage,
a concomitant disease, a non-motor symptom or an emotional
stress factor is complicated because depression does not follow
the same rhythm as other symptoms during PD progression. A
possible explanation may be a deficit in neurotransmitters such
as norepinephrine (Espay et al., 2014) or serotonin (Fox et al.,
2009), suggesting a complementary field of action of chronic
stress in PD through these neurotransmitters (Fitzgerald,
2014).
The idea of emotional stress being implicated in PD onset
has already been supported in some PD patients who previously
suffered the Holocaust (Salganik and Korczyn, 1990). Former
American prisoners of war have roughly twice the rate of death
due to PD (Page and Tanner, 2000). During World War I the
term ‘‘shell shock’’ (currently known as post-traumatic stress
disorder) was coined to describe those soldiers affected by a
diversity of mental disorders resulting from combat stress (Crocq
and Crocq, 2000). In most severe cases, many of the symptoms
observed often remarkably resembled those of PD (Linden
et al., 2013; Djamshidian and Lees, 2014). Among the motor
symptoms recorded, they found mask-like expressions, resting
tremors, postural instability, bradykinesia (slow movements),
rigidity and freezing. Since intense traumatizing_events can
trigger immediate ‘‘shell shock’’ symptoms resembling PD,
it is reasonable to think that mild, but chronic stress may
also elicit ‘‘shell shock’’-like symptoms such as PD in the
long run.
Chronic stress can induce pro-inflammatory cytokine and
chemokine networks. These networks in turn cause a prolonged
activation of the HPA axis (Haddad et al., 2002; McEwen,
2003) creating a cycle that exacerbates inflammation. TNF
levels are increased during long-lasting stress periods in healthy
volunteers (Visnovcova et al., 2015). Increased concentration
of TNF has been found also in the SN of PD patients
(Hirsch and Hunot, 2009). Further, it has been found a
significant correlation between TNF levels and non-motor
symptoms such as cognition, depression and disability in PD
patients (Menza et al., 2010). On the other hand, regulatory
T cells (CD4+ CD25+ FoxP3+) are responsible of maintaining
self-tolerance and controlling immune responses. In this
sense, it was found a 48% reduction in the proportion of
regulatory T cells in post-traumatic stress disorder patients
vs. controls (Sommershof et al., 2009). Similarly, a study
reported lower CD4+/CD8+ ratios and a 24% reduction of
CD4+ CD25+ cells (reaching up to a 64% reduction for
CD4+ CD25high cells) in PD patients (Baba et al., 2005). DA
by itself is able to suppress regulatory T cells and activate
resting effector T cells (CD4+ <<< CD8+), suggesting an
important link between stress, lymphocytes and PD (Levite,
2015).
A review on the literature about the causes of PD concluded
that emotional trauma could be a causative agent (Schwab and
Zieper, 1965). In that article, the authors cited two specific
cases. In one, an individual learned via telegram that his son
had died in a plane that was shot down; in another, a woman
saw her husband being killed in a car accident. In both cases,
symptoms of PD emerged within hours, although such signs
had never been previously detected. There is also a reported
case of a woman who experienced sudden onset PD 1 week
after discovering that her husband was involved in an affair
(Zou et al., 2013). However, another study with more than
13,500 patients showed that the risk of PD was up to 42% lower
among men that had experienced several major life events than
those without any. No other correlation was found for women
(Rod et al., 2010). The authors explained these results in part
due to the fact that PD patients tend to be more cautious and
have premorbid personalities, minimizing risk exposure, which
could reflect an inherited tendency. In this sense, frontotemporal
dementia and parkinsonism has been linked to chromosome 17
(Hong et al., 1998) and some forms of PD are inherited. They
also argue that not all individuals respond equally to major life
events.
Therefore, major life events do not necessarily reflect
perceived stress by the individual and its allostatic load,
meaning the wear and tear effect on the body (McEwen, 2007).
Chronic stress develops from accumulation of little everyday
life events and should, therefore, be approached differently in
studies involving stress and PD. Some authors have established
that stressors, such as job-related events, economic hardship,
disappointment in love, loss of relatives and friends and social
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isolation, may be risk factors for developing PD due to the
important role they play in the mental state of the individuals
affected (Smith et al., 2002; Salmon, 2006; Hemmerle et al.,
2012). The risk of parkinsonism in different occupations has
been studied and authors found that those with daily exposure to
dangerous and/or stressful situations are common occupations
of people who suffer from PD (Goldman et al., 2005; Tanner
et al., 2009). In keeping with this view, Indiana became in
2009 the first state in the U.S.A. to recognize PD as a line of
duty disability among firemen, policemen and EMS responders.
Moreover, according to another study with almost ten thousand
participants, vital exhaustion (a psychological response when
a person is unable to solve or adapt to the source of stress)
may be a pre-motor marker of neurodegeneration leading to
PD (Clark et al., 2013). A symptom of vital exhaustion is
unusual fatigue. Interestingly, mental fatigue, a typical feature
of patients with chronic fatigue syndrome, can be found
in up to 70% of PD patients at some stage of the illness
(Friedman et al., 2011). Chronic fatigue syndrome can increase
some classical PD symptoms in depressed patients including
slow thinking (bradyphrenia), psychomotor retardation or
psychomotor agitation (Lane et al., 1991; Djamshidian and Lees,
2014). In fact, abnormalities in walk movement were detected
in patients with chronic fatigue syndrome (Boda et al., 1995),
suggesting a possible motor dysfunction similar to that seen in
PD patients. Stress can increase the symptoms of PD, such as
tremor after episodes of anxiety or anger (Djamshidian and Lees,
2014).
Although typical clinical features of PD include motor
symptoms, the disease also include some non-motor
disturbances, such as autonomic dysfunction as well as
neuropsychiatric problems such as depression, mood changes
and pain. It is known that stress can transiently increase motor
symptoms of PD, and a positive association between cortisol
and gait deficits has been shown (Charlett et al., 1998). Several
studies also discuss how stress may deteriorate the symptoms
of PD patients, such as bradykinesia and akinesia, the difficulty
to initiate movements, sudden motor blocks (freezing), and
tremor (Schwab and Zieper, 1965). Moreover, stress can also
affect some nonmotor signs of PD. Individuals with PD have
reduced hedonic responses after exposure to emotional stress
(Macht et al., 2007). These authors demonstrated that hedonic
responses of PD patients were reduced by stress, being this effect
independent from depressive mood. The authors suggested that
the ability to respond in an emotionally positive manner to
external stimuli may be reduced in PD.
Stress has also been considered to influence not only the
diversity in symptoms and course of PDwithin different patients,
but also their individual responses to medication after the
onset of the disease (Foley et al., 2004). This might depend
on the extension of dopaminergic damage, so that stress could
make abruptly appear an altered behavior that was hidden
in a preclinical phase. Supporting this, experiments on rats
showed that drugs enhancing dopaminergic function reversed
neurological deficits induced by stress, while harmful effects of
stress were increased by dopaminergic antagonists (Snyder et al.,
1985).
However, the greatest risk factor for PD appears to be age,
since the symptoms of PD emerge preferentially after the age
of 65. In this regard, it is important to note that dysfunctions
in the stress response develop during the aging process. Hence,
as an organism ages, the response of the HPA axis to stress
becomes hyperactive and less efficient to return to former
homeostatic conditions, thus exposing brain cells to higher levels
of GCs for longer periods of time (Stein-Behrens et al., 1992).
Taking into account that another factor in the late onset of
PD is the increased vulnerability of DA neurons to insults, the
deregulation of the HPA axis might render cells in the aged
brain more susceptible to degeneration in the face of subsequent
stress.
High levels of cortisol have been found in PD patients
(Hartmann et al., 1997; Charlett et al., 1998; Djamshidian
and Lees, 2014). High levels of cortisol provoked by a
dysfunctional HPA axis have been associated to dopaminergic
cell loss and motor disability (Müller and Muhlack, 2007,
2008). However, a relative diurnal decrease of 22% in
cortisol secretion in PD patients vs. controls has been
reported (Hartmann et al., 1997). They postulated that a
decreased expression of hippocampal MRs in PD patients
may explain such reduction (Hartmann et al., 1997). All
these data point out that stress could be an important
factor in the development of PD. Measurement of stress
hormones such as salivary cortisol levels (Djamshidian
and Lees, 2014), inflammatory markers such as cytokines
(Hirsch and Hunot, 2009), and the roles of physical
exercise and cognitive behavioral therapy are potential
lines of future research that may further clarify the role of
stress in PD.
Concluding Remarks
Accumulating evidence demonstrates how stress-related GCs
may sensitize microglia to subsequent pro-inflammatory
challenges, thus enhancing the brain inflammatory response
(Figure 2). Excessive pro-inflammatory microglia activation
may be neurotoxic, thus bringing a rationale between chronic
stress and the progression of different neurodegenerative
diseases, particularly PD. The potential involvement of brain
inflammation in the etiology of PD is well established.
Consequently, stress-related GCs may be an important
contributing factor to modulate the long-term brain
inflammatory response, including the appearance of neurotoxic
microglia. Since midbrain dopaminergic neurons are especially
sensitive to pro-inflammatory microglia, the impact of chronic
stress in the etiology and course of PD deserves a special
attention.
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